GRB2

Bio-Path Holdings Provides 2024 Clinical and Operational Update

Retrieved on: 
화요일, 4월 2, 2024
Toxicity, Obesity, Drug discovery, Chronic lymphocytic leukemia, Survival, CLL, AML, Fast track (FDA), Insulin, Patient, New York Medical College, Biomarker, Cancer, Leukemia, IND, University, Lymphoma, Pancreatic cancer, Clinical trial, Paclitaxel, Potential, Breast cancer, Safety, RNA interference, GRB2, Holding, Leptin, Probability, FDA, STAT3, Stage 4, Food, Pharmaceutical industry

HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update for 2024.

Key Points: 
  • HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update for 2024.
  • Prexigebersen Phase 2 Clinical Trial – Bio-Path’s Phase 2 clinical trial is treating Acute Myeloid Leukemia (AML) patients.
  • Phase 1/1b Clinical Trial in BP1002 in Relapsed/Refractory AML – A Phase 1/1b clinical trial for BP1002 to treat relapsed/refractory AML patients, including venetoclax-resistant patients, is ongoing.
  • In January 2024, Bio-Path announced successful completion of the first dose cohort in the Phase 1 clinical trial.

Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

Retrieved on: 
월요일, 7월 17, 2023
Holding, GRB2, Paclitaxel, MD Anderson Cancer Center, Patient, University, Lung, RNA interference, Safety, Disease, Pharmaceutical industry

The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days.

Key Points: 
  • The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days.
  • Three patients were enrolled into the first dose cohort of BP1001-A at 60 mg/m2 at three different centers in the study, including one patient with hepatic lesions (and lung metastases) and two with advanced gynecologic lesions.
  • All three patients had undergone extensive previous chemotherapies and/or surgeries for their disease prior to enrollment in this Phase 1 study.
  • No patient experienced any treatment related adverse events or any adverse events deemed related to the study drug.

Bio-Path Holdings Reports Full Year 2022 Financial Results

Retrieved on: 
금요일, 3월 31, 2023
Holding, GRB2, Clinical trial, Hope, Acute myeloid leukemia, AML, Patient, Cancer, Research, Safety, Pharmaceutical industry, Medical imaging, Cryptocurrency

“We see continued enthusiasm from clinical investigators and patients alike and hope to make even more progress toward completing these key studies.

Key Points: 
  • “We see continued enthusiasm from clinical investigators and patients alike and hope to make even more progress toward completing these key studies.
  • As of December 31, 2022, the Company had cash of $10.4 million, compared to $23.8 million at December 31, 2021.
  • Net cash provided by financing activities for the year ended December 31, 2022, was $1.7 million.
  • ET to review these full-year 2022 financial results and to provide a general update on the Company.

Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

Retrieved on: 
수요일, 12월 7, 2022
University, Intellectual property, Annual report, Security (finance), Neoplasm, Lymphatic system, Safety, Lymphoma, Maintenance, GRB2, RNA interference, STAT3, Acute myeloid leukemia, Paclitaxel, MD Anderson Cancer Center, IND, Patent, Uncertainty, Holding, COVID-19, Patient, Pharmaceutical industry

The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days.

Key Points: 
  • The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days.
  • The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia.
  • This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws.
  • Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Bio-Path Holdings Reports Third Quarter 2022 Financial Results

Retrieved on: 
화요일, 11월 15, 2022
COVID-19, Drug discovery, Patient, AML, IND, RNA interference, Holding, Acute myeloid leukemia, GRB2, Annual report, Maintenance, Research, Patent, Security (finance), Sale, STAT3, Intellectual property, Lymphoma, Uncertainty, FDA, Lymphatic system, Pharmaceutical industry

HOUSTON, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2022 and provided an update on recent corporate developments.

Key Points: 
  • HOUSTON, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2022 and provided an update on recent corporate developments.
  • The third quarter was marked by continued progress across our entire DNAbilize pipeline.
  • As of September 30, 2022, the Company had cash of $13.7 million, compared to $23.8 million at December 31, 2021.
  • ET to review these third quarter 2022 financial results and to provide a general update on the Company.

Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022

Retrieved on: 
화요일, 11월 8, 2022
GLOBE, IND, Lymphoma, Holding, GRB2, Acute myeloid leukemia, Technology, STAT3, NASDAQ, RNA interference, Lymphatic system, FDA, Pharmaceutical industry

ET to report financial results for the third quarter ended September 30, 2022 and to provide a business overview.

Key Points: 
  • ET to report financial results for the third quarter ended September 30, 2022 and to provide a business overview.
  • To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time.
  • A live audio webcast of the call will also be available on the Presentations section of the Companys website, www.biopathholdings.com .
  • In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2022 or first quarter 2023.

Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement

Retrieved on: 
월요일, 11월 7, 2022
GRB2, Exercise, RNA interference, LLC, Maintenance, Sale, Patent, GLOBE, Lymphoma, Holding, FDA, Intellectual property, IND, Uncertainty, Acute myeloid leukemia, COVID-19, Intention, Securities Act of 1933, Regulation D, Annual report, U.S. Securities and Exchange Commission, STAT3, NASDAQ, Lymphatic system, Form, Technology, Security (finance), SEC, Roth Capital Partners, Pharmaceutical industry

Additionally, in a concurrent private placement, Bio-Path has also agreed to issue to such investors unregistered warrants.

Key Points: 
  • Additionally, in a concurrent private placement, Bio-Path has also agreed to issue to such investors unregistered warrants.
  • The offerings are expected to close on or about November 9, 2022, subject to the satisfaction of customary closing conditions.
  • Roth Capital Partners is acting as the sole placement agent for the offerings.
  • A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov .

Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Retrieved on: 
월요일, 10월 24, 2022
U.S. Securities and Exchange Commission, Uncertainty, RNA transfection, Medicine, Hospital, Acute myeloid leukemia, IND, AML, MD Anderson Cancer Center, Lymphoma, Weill Cornell Medicine, Annual report, NASDAQ, GRB2, Patient, RNA interference, Joe Byrd (Cherokee Nation Principal Chief), Lymphatic system, Scripps Health, Security (finance), STAT3, Clinical, Cornell University, Technology, University, Department, Patent, Safety, Intention, GLOBE, Clinical trial, Maintenance, Intellectual property, Life expectancy, Holding, COVID-19, BH3, Cancer, D.O, Pharmaceutical industry, Decitabine

We are delighted to have dosed the first patient in this key clinical trial.

Key Points: 
  • We are delighted to have dosed the first patient in this key clinical trial.
  • BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers.
  • By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
  • The Companys second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia.

Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
화요일, 9월 6, 2022
RNA interference, Technology, IND, NASDAQ, STAT3, Acute myeloid leukemia, Lymphatic system, Lymphoma, GLOBE, Conference, FDA, Holding, GRB2, Pharmaceutical industry

ET.

Key Points: 
  • ET.
  • An audio webcast of the presentation will be available here and on the InvestorRelations section of Bio-Paths website, where it will be archived for approximately 90days.
  • Bio-Path is a biotechnology company developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion.
  • The Companys second product BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia.

Bio-Path Holdings Reports Second Quarter 2022 Financial Results

Retrieved on: 
화요일, 8월 16, 2022
FDA, Public relations, Intellectual property, U.S. Securities and Exchange Commission, Acute myeloid leukemia, Association, American Association, GLOBE, Breast, Technology, Cancer, Poster, IND, Board, Patent, Security (finance), Annual report, AML, Lymphatic system, Patient, Review, COVID-19, Company, Lymphoma, American Association for Cancer Research, Paclitaxel, RNA interference, NASDAQ, Intention, AACR, Research, Uncertainty, Maintenance, STAT3, Board of directors, Holding, GRB2, Pharmaceutical industry

HOUSTON, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2022 and provided an update on recent corporate developments.

Key Points: 
  • HOUSTON, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the second quarter ended June 30, 2022 and provided an update on recent corporate developments.
  • Throughout the second quarter and in recent weeks, we have made substantial operational progress as we continue to advance our DNAbilize platform of products along the clinical pathway.
  • In April, Bio-Path presented a poster highlighting preclinical BP1003 data at the 2022 AACR Annual Meeting.
  • ET to review these second quarter 2022 financial results and to provide a general update on the Company.